Skip to content
Review

Overcoming glioma heterogeneity: Strategies to improve the specificity of oncolytic viruses.

Oct 2026 · Pathology, Research and Practice · Vol 289, pp. 156717 · 0 citations · 135 references
Medicine

TL;DR

This review examines how genetic, transcriptional, metabolic, epigenetic, and immune heterogeneity influence viral entry, replication, dissemination, and therapeutic activity in glioma and compares established and emerging platforms.

Abstract

High-grade gliomas remain difficult to treat because of their infiltrative growth, cellular heterogeneity, and resistance to conventional therapies. Oncolytic viruses (OVs) offer a therapeutic approach that combines preferential viral replication in malignant cells with activation of antitumor immunity. However, heterogeneous receptor expression, intracellular antiviral defenses, limited intratumoral distribution, and central nervous system safety constraints complicate clinical translation. This review examines how genetic, transcriptional, metabolic, epigenetic, and immune heterogeneity influence viral entry, replication, dissemination, and therapeutic activity in glioma. We compare established and emerging platforms, including adenovirus, herpes simplex viruses, PVSRIPO, measles virus, vaccinia virus, and M1 alphavirus, while distinguishing preclinical findings from clinical evidence. We also discuss approaches to tumor selectivity, delivery, immune microenvironment remodeling, and combination checkpoint blockade. Clinical studies demonstrate feasibility and occasional durable responses, but most are small and uncontrolled, and early activity has not consistently translated into benefit in larger trials. Progress requires platform-specific biomarkers, representative experimental models, rigorous neurological safety assessment, and controlled clinical evaluation. Improving specificity must therefore be considered together with tumor coverage, immune function, and clinically meaningful outcomes.

View source

Similar papers

Review Open access Nov 2026

Advancements in oncolytic virus therapy: a new horizon for ovarian cancer

Ovarian cancer remains the most lethal gynecological malignancy, and the limited durability of standard treatments has motivated the development of new therapeutic strategies. Oncolytic viruses selectively replicate within and lyse tumor cells, releasing tumor antigens and inflammatory signals that can convert an immun...

Qiu-Man Wang, Yu Sun, Ru-Xin Liu et al. · 0 citations
Review Open access Oct 2026

Oncolytic virotherapy for cancer: biological mechanisms, clinical advances, and future perspectives

Oncolytic virotherapy has emerged as a promising cancer treatment that combines selective tumor destruction with potent stimulation of antitumor immunity. Unlike conventional therapies, oncolytic viruses (OVs) preferentially infect and replicate within malignant cells while sparing normal tissues, leading to direct tum...

Esraa M. Halawa, Sherihan G. Abdelhamid, Mahmoud M. Elhefnawi · 0 citations
Review Open access Sep 2026

Oncolytic virotherapy at the tumor microenvironment-CAR Therapy interface: Mechanisms, clinical translation, and future directions.

Oncolytic virotherapy has evolved from a tumor-selective cytolytic strategy into a programmable immunotherapeutic platform that reshapes the tumor microenvironment (TME). Oncolytic viruses (OVs) selectively infect malignant cells, induce immunogenic cell death, release tumor antigens, and activate innate and adaptive i...

A. Atoom, J. Rizaev, D. Polatova et al. · 0 citations
Review Open access Oct 2026

Oncolytic Viruses as In Situ Cancer Vaccines: Tumor Microenvironment Remodeling, Checkpoint Inhibitor Synergy, and Biomarker-Guided Clinical Translation

Oncolytic viruses (OVs) are increasingly viewed not only as tumor-lysing agents but also as immunotherapeutic platforms capable of functioning as in situ cancer vaccines. By selectively infecting malignant cells, inducing immunogenic cell death, releasing tumor-associated antigens and danger signals, and activating inn...

Kamil Rogalski, Michał Iwaszko, Anna Kuraś et al. · 0 citations
Review Open access Oct 2026

Advances in targeted delivery and combination immunotherapy of oncolytic viruses for glioma

Glioblastoma (GBM), as the most lethal malignancy of the central nervous system, faces the dual constraints of the physical barrier of the blood-brain barrier (BBB) and a highly immunosuppressive microenvironment, rendering conventional immunotherapies largely ineffective. Oncolytic viruses (OVs), which possess a d...

Yuxuan Liu, Yue-Jia Ding, Jian-Shuang Chen et al. · 0 citations
Review Open access Sep 2026

Oncolytic Virus-Based Immunotherapy: Mechanistic Insights, Synergistic Design and Translational Frontiers

Oncolytic viruses (OVs) can selectively lyse tumor cells and remodel the immunosuppressive tumor microenvironment. However, monotherapy is limited by low response rates, systemic delivery barriers and antiviral-mediated viral clearance. Combinatorial strategies with immune-checkpoint inhibitors, CAR-T cells, cancer vac...

Yi-Xuan Tao, Xue-Min Chen, Ao Ye et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.